Psilocybin, a psychoactive compound found in magic mushrooms, is approved in Australia for use in treatment-resistant depression.

But a new study suggests the benefits of psilocybin in these patients might not be as effective as past clinical trials have suggested.

In 2023, Australia became the first country in the world to legalise the use of psychedelics to treat some mental health conditions.

Guest/s

• Associate Professor Fredrik Hieronymus, Group leader of the clinical psychopharmacology group, University of Gottenburg

References

• Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression